Ceramide and phosphatidylcholine lipids‐based risk score predicts major cardiovascular outcomes in patients with heart failure

Documenti analoghi

• Treatment strategies to reduce cardiovascular risk in persons with chronic kidney disease and Type 2 diabetes
  di: Faiez Zannad, et al.
  Pubblicazione: (2024)
• Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR‐Pooled analysis
  di: Khawaja M. Talha, et al.
  Pubblicazione: (2024)
• Post‐Mortem Identification and Toxicological Findings of Fluetonitazepyne and Isotonitazepyne
  di: Pirkko Kriikku, et al.
  Pubblicazione: (2025)
• Ceramide‐based risk score CERT‐1 improves risk prediction for overall mortality and adverse cardiovascular outcomes in patients with and without cardiovascular disease: A prospective cohort study
  di: Alessandro Mantovani, et al.
  Pubblicazione: (2024)
• MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials
  di: Faiez Zannad, et al.
  Pubblicazione: (2024)